Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency
10.12092/j.issn.1009-2501.2023.02.008
- Author:
Yong PENG
1
;
Jianfeng FAN
1
;
Xuhua XIONG
1
;
Dongping XIAO
1
;
Zhaobo GAO
1
;
Chunhua ZHENG
1
Author Information
1. The Second Department of Cardiology, The Third Affiliated Hospital of Nanchang University
- Publication Type:Journal Article
- Keywords:
heart failure;
iron deficiency;
iron dextran dispersible tablets;
reduced ejection fraction
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(2):178-183
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To evaluate the clinical effect of Iron Dextran Dispersible Tablets on patients with chronic heart failure who reduced ejection fraction after 24 weeks. METHODS: From January 2020 to June 2022, forty-five patients with heart failure complicated with iron deficiency and reduced ejection fraction were selected as the research objects. According to the random number table, they were randomly divided into control group and observation group.The control group was given routine anti-heart failure treatment such as Sacubitril Calsartan sodium tablets, while the observation group was given iron dextran dispersible tablets 50 mg three times a day on the basis of the anti-heart failure treatment of the control group for 8 weeks. The 6-minute walking distance, Hemoglobin, Serum Ferritin, N-terminal B-type natriuretic peptide precursor, Left Ventricular Ejection Fraction, Left Ventricular end Diastolic Diameter and 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score and clinical summary score were compared between the two groups. RESULTS: There was no significant difference in baseline data between the two groups (P > 0.05). After treatment, the 6-minute walking distance in the observation group was longer than that in the control group, while the serum ferritin level in the observation group was higher than that in the control group. The N-terminal pro-B-type natriuretic peptide level in the two groups was lower than that before treatment, and the left ventricular end diastolic diameter was shorter than that before treatment, and the left ventricular ejection fraction, clinical comprehensive score and symptom score were higher than that before treatment. The difference was statistically significant (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05). CONCLUSION: Iron Dextran Dispersible Tablets can improve the exercise endurance and quality of life of patients with chronic heart failure who reduced ejection fraction after 24 weeks.
